Sharing best practices to improve cardiovascular and diabetes health.
Founded in 2017, the mission of Cardi-OH is to improve cardiovascular and diabetes health outcomes and eliminate disparities in Ohio's Medicaid population.
Body
MOST RECENT
Study Shows Efpeglenatide Lowers Cardiovascular Disease Risk in High-Risk Patients with Type 2 Diabetes
The June 2021 AMPLITUDE-O study evaluated the use of efpeglenatide in patients with type 2 diabetes mellitus who had either a history of cardiovascular (CV) disease or current kidney disease plus one additional CV risk factor. This randomized controlled trial evaluated CV risk reduction in patients taking weekly subcutaneous injections of efpeglenatide, a novel exendin-based glucagon-like peptide-1 receptor agonist (GLP-1 RA). Prior studies established CV risk reduction properties of analogs to human GLP-1; however, a dedicated outcomes trial of another exendin-based molecule (exenatide once weekly) did not demonstrate CV benefit which raised concerns that the CV benefit from GLP-1-based therapies was not a class effect.
Body
What We Do
How We Do It
Why We Do It
Body
